A carregar...
DUO delivers for duvelisib
In this issue of Blood, Flinn et al report the final results of the phase 3 registration trial DUO,(1) which compared the novel PI3Kδ,γ inhibitor duvelisib with ofatumumab in patients with relapsed refractory chronic lymphocytic leukemia (CLL) and demonstrated a significant improvement in progressio...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6284219/ https://ncbi.nlm.nih.gov/pubmed/30523122 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-10-879650 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|